Oxford Pharmascience (OXP)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 13.0 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +10.7% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Oxford Pharmascience Group Plc revenues increased 65% to L466K. Net loss decreased 15% to L783K. Revenues reflect Brazil segment increase of 59% to L333K. Lower net loss reflects Finance Income increase from L0K to L2K (income). more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
Oxford Nutrascience Group Plc is a United Kingdom-based holding company. The Company, along with its subsidiaries, is engaged in the development and commercialization of delivery systems for vitamins and medicines. In addition to developing and marketing its own dossiers, the Company works with pharmaceutical companies to develop new products for generic active pharmaceutical ingredient (API's). Its technology portfolio includes delivery systems for chewable tablets, liquid suspensions, and solid state suspensions (soft chews), as well as its drug delivery technology for taste making. The Company works with a range of partners in the pharmaceutical technology, drug delivery science, regulatory and manufacturing to provide a full product development solution. The Company's taste masking technology has allowed the Company to develop a taste-masked ibuprofen material with an ibuprofen content of circa 50%. On January 27, 2010, the Company acquired Oxford Nutrascience Limited.
Directors: Nigel Theobald (CEO) , Michael Bretherton (Fin. Dir.) 56, Marcelo Bravo (CTO) , Christopher Hill (Secy.) ,
No. of Employees: 7 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 730,869,952 |
| Free Float | 417.1m (57.1%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Centre for Innovation & Enterprise,Begbroke HillWoodstock Road Begbroke, OXFORD, OX5 1PF, United Kingdom |
| Web | http://www.oxfordpharmascience.com/ |
| Phone | +44 1865 854874 |
| Contact | () |
| Registrar | Capita Registrars Limited (Huddersfield) |
| Auditors | RSM Tenon Audit Limited |
| 8th May | Successful study & NSAID programme initiated |
| 22nd Mar | Holding(s) in Company |
| 20th Mar | Holding(s) in Company |
| 20th Mar | Final Results |
| 19th Mar | Result of EGM |
| 27th Feb | Placing and Notice of General Meeting |
Recent ↓
